EUCTR2009-017044-13-HU进行中（未招募）不适用
A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluatethe Effect of Remission Status on the Ability to Maintain or AchieveClinical and Endoscopic Remission During a 12-Month, Long-termMaintenance Phase With 2.4g/day MMX® Mesalamine/mesalazineOnce Daily in Adult Subjects With Ulcerative Colitis - MOMENTUM
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects meeting all of the criteria listed below at screening may be included in the study:
- •1. Adults aged 18 years or older.
- •2. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol.
- •3. Diagnosis of active mild to moderate UC (acute flare or suspected newly diagnosed with a total score of 4–10 inclusive on the modified UC-DAI with an endoscopy score of =1 and a PGA of =2)*. The original diagnosis of UC must be established by sigmoidoscopy or colonoscopy, and have compatible histology (performed prior to screening). An endoscopy with biopsies taken for confirmatory histology will be performed during the screening period for suspected newly diagnosed subjects only.
- •4. Stable maintenance therapy of 5-ASA =3.2g/day (excluding MMX mesalamine/mesalazine), if 5-ASA is being taken at the onset of acute flare. Stable maintenance therapy is defined as no change in dose, or no initiation of 5-ASA, from the onset of the acute flare through baseline.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 338
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Subjects are excluded from the study if any of the following criteria are met at screening:
- •1. Severe UC (assessed by PGA =3).*
- •2. Acute flare with onset >6 weeks prior to Baseline (Visit 0) while on maintenance therapy. There is no limit to the onset of flare prior to Baseline (Visit 0) if the flare is untreated.
- •3. Acute flare while on maintenance MMX mesalamine/mesalazine (LIALDA®, MEZAVANT®, MEZAVANT® XL,MEZAVANT® LP).
- •4. Unsuccessfully treated current acute flare using steroids or 5-ASA doses >3.2g/day.
- •5. Acute flare on a 5-ASA maintenance therapy of >3.2g/day.
- •6. Systemic or rectal steroids use within the 4 weeks prior to screening or immunosuppressants within the last 6 weeks prior to screening.
- •7. History of biologic (anti-TNF agent) use.
- •8. Antibiotic use or repeated use (>3 consecutive days of use at doses above the prescribed over-the-counter dose) of any anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs such as aspirin, COX-2 inhibitors or ibuprofen, within 7 days prior to screening. However, prophylactic use of a stable dose of aspirin up to 325mg/day for cardiac disease is permitted.
- •9. Current or recurrent disease, other than UC, that could affect the colon, the action, absorption, or disposition of the investigational medicinal product, or clinical or laboratory assessments.
- •* The symptom parameters of the modified UC-DAI (rectal bleeding and stool frequency) will be assessed at screening and Baseline (Visit 0). Endoscopy scores will be obtained at Baseline (Visit 0) to confirm eligibility, except in the case of suspected newly diagnosed subjects only, where endoscopy with biopsies taken for both confirmatory histology and for central laboratory assessment will be performed during the screening period. For all subjects (including suspected newly diagnosed subjects), the PGA, assessment of subject's symptoms, and calculation of total UC-DAI score will be performed at Baseline (Visit 0).
研究者
相似试验
招募中
3 期
A clinical trial to study the percentage of subjects in complete (clinical and endoscopic) remission after 12 months of maintenance treatment with 2.4g/day MMXmesalamine/mesalazine given once daily (QD) between subjects who were in complete remission and subjects who were in partial remission at the end of 8 weeks acute treatment with 4.8g/day MMX mesalamine /mesalazine given QD.CTRI/2010/091/001221Shire Development Inc.725 Chesterbrook BoulevardWayne, Pennsylvania 19087,695
进行中（未招募）
不适用
A study to Evaluate the Ability to Maintain Clinical andEndoscopic Remission During a 12-Month period with 2.4g/day of druggiven once a day in adults with ulcerative colitislcerative ColitisMedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2009-017044-13-IEShire Development LLC1,000
进行中（未招募）
1 期
A study to Evaluate the Ability to Maintain Clinical and Endoscopic Remission During a 12-Month period with 2.4g/day of drug given once a day in adults with ulcerative colitisEUCTR2009-017044-13-BEShire Development LLC1,000
进行中（未招募）
1 期
A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluatethe Effect of Remission Status on the Ability to Maintain or AchieveClinical and Endoscopic Remission During a 12-Month, Long-termMaintenance Phase With 2.4g/day MMX® Mesalamine/mesalazineOnce Daily in Adult Subjects With Ulcerative ColitisEUCTR2009-017044-13-FRShire Development Inc1,000
进行中（未招募）
不适用
A study to Evaluate the Ability to Maintain Clinical and Endoscopic Remission During a 12-Month period with 2.4g/day of drug given once a day in adults with ulcerative colitisUlcerative ColitisEUCTR2009-017044-13-DEShire Development Inc1,000